| Literature DB >> 30461262 |
Kevin M Koo1, Shuvashis Dey1, Matt Trau1,2.
Abstract
The use of circulating tumor nucleic acids (ctNA) in patient liquid biopsies for targeted genetic analysis is rapidly increasing in clinical oncology. Still, the call for an integrated methodology, which is both rapid and sensitive for analyzing trace ctNA amount in liquid biopsies, has unfortunately not been fully realized. Herein, we performed complex liquid biopsy sample-to-targeted genetic analysis on a biochip with a 50 copies-detection limit within 30 min. Our biochip uniquely integrated the following: (1) electrical lysis and release of cellular targets with minimal processing; (2) nanofluidic manipulation to accelerate molecular kinetics of solid-phase isothermal amplification; and (3) single-step capture and amplification of multiple NA targets prior to nanozyme-mediated electrochemical detection. Using prostate cancer liquid biopsies, we successfully demonstrated multifunctionality for cancer risk prediction; correlation of serum and urine analyses; and cancer relapse monitoring.Entities:
Keywords: liquid biopsy; microfluidics; prostate cancer; risk stratification; solid-phase amplification
Mesh:
Substances:
Year: 2018 PMID: 30461262 DOI: 10.1021/acssensors.8b01011
Source DB: PubMed Journal: ACS Sens ISSN: 2379-3694 Impact factor: 7.711